Gatifloxacin for Enteric Fever
|
|
- Deirdre Briggs
- 6 years ago
- Views:
Transcription
1 This document contains information on the patent status for gatifloxacin from two sources: 1. Dae Oh. Drugs in Focus: Gatifloxacin (downloaded on 10Nov2010) 2. A search commissioned to Withers&Rogers by WHO/TDR Drug In Focus: Gatifloxacin Gatifloxacin, a fluoroquinolone antibiotic, marketed by Allergan under the brand name Zymar, will lose its active ingredient patent protection in the US in June this year. This month's Drug In Focus will analyse the patent landscape surrounding Gatifloxacin based on information contained in GenericsWeb's Gatifloxacin Pipeline Selector report. Table 1: Gatifloxacin General Information The Zymar product is formulated as ophthalmic solution/drops and indicated for the treatment of bacterial conjunctivitis as shown in the Gatifloxacin General Information (Table 1). The Tequin products, in the dosage form of tablets and intravenous liquid, for the treatment of chronic bronchitis have been withdrawn by Bristol-Myers Squibb from the US and Canadian markets since This withdrawal was due to the side effects of these products on the blood-sugar complications in diabetics and elderly patients. As a result, the Zymar product is the only listed product containing Gatifloxacin in the US Orange Book and Canadian Patent Register. According to Verispan, an independent research firm, Zymar was the number two ophthalmic antiinfective prescribed by ophthalmologists in the United States in APPENDIX 1-1
2 Table 2: Gatifloxacin Key Patent Indicator The Gatifloxacin Key Patent Indicator (KPI) in Table 2 shows four patent families. Patents in the first family protect the Gatifloxacin active ingredient via claims to its chemical formula. In this family, US will expire on 15 June 2010 due to the grant of 6 months paediatric exclusivity, in addition to the USC s156 patent term extension grant of 721 days. US , claiming other analogues of Gatifloxacin, expired in August The British and French patents in this family expired in 2007, but the German equivalent will not expire until 2012 due to a granted SPC application. AU will expire in January 2012 due to a grant of s70 extension. Both the Australian and German extensions are based on the marketing authorisation of the Tequin products, which are now discontinued in those countries. This is also suggested by the Regulatory Data in the Pipeline Selector report, where no marketing authorisation holders for any Gatifloxacin products exist in Australia, France or Great Britain. Canada has the latest expiring member of the family with CA being valid until January 2016 due to its term being calculated from the issue date. It is clear that any generic manufacturer would need to wait until at least the expiry of appropriate patents in this family before commercialising a generic equivalent. The second KPI family protects a sesquihydrate of Gatifloxacin. The normal term of members of APPENDIX 1-2
3 this patent family expires in December 2015, however US expires in June 2016 due to the grant of a paediatric extension. This family may not be a great concern for generic manufacturers since those who conducted their patent research in advance would possibly be able to circumvent this family by developing and using different hydrates of Gatifloxacin in the finished dosage form. This type of thinking is confirmed by information found under the Gatifloxacin Drug Master Files (DMF), showing 5 generic companies holding active DMFs. Among them, Apotex is using Gatifloxacin hemihydrate whilst Cadila is using anhydrous Gatifloxacin as an active ingredient instead of the protected Gatifloxacin sesquihydrate. The use of a different hydrate for manufacture of the dosage form by Apotex could be one of the reasons that Allergan did not sue Apotex for infringement of US when they filed an ANDA with Paragraph IV certification in October 2007 (as identified in the Litigation Alert and Paragraph IV sections of the Pipeline Selector report). The third KPI family protects aqueous liquid formulation comprising Gatifloxacin and disodium edetate, which is one of the inactive ingredients found in the Zymar product. Australian, Canadian, and European members of this family all expire uniformly in August 2019, while US expires in February 2020 due to the grant of paediatric exclusivity. This family would be a great concern for generic developers since they would either need to invalidate the patent or find a way to formulate their version of the product using a different chelating agent which has similar properties to disodium edetate and which does not fall into the scope of Doctrine of Equivalents test, if applied by the US courts. The Pipeline Selector Litigation Alert for US shows that Allergan sued Apotex in the district court of Delaware in November 2007, asserting infringement of the US patent only following Apotex s submission of the ANDA with a Paragraph IV certification to manufacture a generic Zymar. In response, Apotex counterclaimed, declaring the US patent invalid and unenforceable because the patentee did not disclose important information during prosecution at the USPTO. The outcome of the trial is not yet known (the trial began only last week), the FDA has already granted the only tentative approval for Apotex s generic Zymar in June last year, suggesting that Apotex have a good chance to be the first generic developer to enter the US market with this product. Although other Paragraph IV filings were made earlier by other generic companies such as Teva, these were in relation to the withdrawn Tequin oral Gatifloxacin product, thus Apotex may benefit from a 180-day market exclusivity for generic versions of Zymar in return for being the first filer with Paragraph IV certification, if their patent challenge is successful. The final KPI family protects a formulation comprising crystalline co-precipitate of Gatifloxacin and a fatty acid selected from stearic acid, palmitic acid and mixtures thereof. Interestingly, US has been delisted from the Orange book as it can be seen from the update column of the Patent Publication Detail (Table 3), which is one of the new features of Pipeline Selector reports. APPENDIX 1-3
4 Table 3: Gatifloxacin Patent Publication Detail One of the reasons for de-listing could be the fact that the discontinued Tequin products contain one of the fatty acids while the currently marketed Zymar product does not contain the fatty acid. All the equivalent patent applications in other territories have been withdrawn. This family does not appear to be a barrier for generic manufacturers to develop the Zymar product. To summarise the key patent families, it appears that the Apotex tentative approval will become final upon expiry of the molecule patent in June 2010 (although this could not be confirmed at the time of writing). At this stage, Apotex would then need to make a Launch at Risk decision in regard to the 045 patent, assuming that a) their product falls within the scope of the patent and b) any appeal following the initial judgement would not have been heard before such time. The final key patent family has been delisted and is clearly not relevant to the current Zymar product, however the 283 sesquihydrate patent may have been considered differently by the innovator following a recent case relating to Ropivacaine (thanks to IP Think Tank). This involved expert testimony that hydrates may not fully dissociate in solution and so a hydrate patent may still be infringed even if the active ingredient has been dissolved into a true solution. The main support for Apotex in this case would have been that the subject of their DMF is the hemihydrate form, thus the assertion that the sesquihydrate exists in solution would be a difficult one to prove. When the generic strategy is to circumvent Orange-Book listed patents, extreme caution is required when selecting a formulation since a great number of patents claiming different types of formulations, which are not listed in the Orange book, might have already been filed and/or granted for this product. This situation can be confirmed by the Patent Risk Analysis section of the Gatifloxacin Pipeline Selector report (Figure 1), based on comprehensive patent information (details of which are available by subscribing the corresponding Pipeline Developer report). It indicates that the patenting activity relating to this drug has focused on formulations, with almost half of the total number of Gatifloxacin related patent families falling into this category. APPENDIX 1-4
5 Figure 1: Gatifloxacin Patent Category Distribution This is further re-confirmed by the Patent Filing Trends (Figure 2) which shows significant increase of overall patent applications, particularly formulations related applications, since the major launch of Gatifloxacin products in This abrupt increase in filing suggests that generic pharmaceutical companies have become interested in developing a generic version of this product and this suggestion can be confirmed by the corresponding Pipeline Developer report for this drug. Figure 2: Gatifloxacin Patent Filing Trends In summary, although the Tequin products are withdrawn from the market, there still appears to be strong interest by at least one generic pharmaceutical company to enter the US market with a generic equivalent of the remaining Zymar product. The innovators have undertaken active life cycle management by not only relying on the patent protecting the active ingredient APPENDIX 1-5
6 but also seeking patent protection regarding molecular forms and formulations, something that may prove valuable in the coming months and years. Nevertheless there will always be an opportunity for proactive generic pharmaceutical companies to share the market with the innovators. It is likely that Apotex will be one of the first generic to enter the market with their proactive approach regarding this product. However, other generic developers still have an opportunity to enter the market with their own generic version of formulations regarding this product once any 180 day exclusivity period has expired. Generic developers are strongly advised that a comprehensive search of the patent landscape laid around Gatifloxacin is a crucial step before any technical development takes place in order to avoid costly litigation, particularly in regard to formulations. Obviously, this would not be possible without first comprehensively identifying relevant patents from the over 50 million published patent documents worldwide, and keeping this information up to date. Comprehensive data for patent families relating to Gatifloxacin, based on professional patent searching, may be accessed by subscribing to the GenericsWeb Pipeline Developer report which includes twelve monthly updates to keep you abreast of recently published patents and applications. GenericsWeb Pipeline Selector reports are available for any active ingredient upon request. For questions and comments about this article please contact the author at d.oh@genericsweb.com APPENDIX 1-6
7 Withers & Rogers GATIFLOXACIN PATENT SEARCH No. Country Patent No. Expiry date (Inclusive of SPC) Australia Austria Belgium France Italy Liechtenstein Greece Hungary China Finland Denmark Ireland Germany Brazil Norway Japan Netherlands Luxembourg Spain Sweden Switzerland UK USA South Korea Czech Republic Slovak Republic a) AU b)au EP EP HU a) CN b) CN Application No: 87/1419 Application No: 87/ 1642 Application No: 87/826 EP BR Application No. 87/1333 a) JP 87/ b) JP 91/ 7261 c) JP 93/81590 d) JP 96/ 9597 EP EP a) US b) US Application no. 94/7308 Application no. 94/4171 Application no. 94/4171 a) January 19, 2012 b) March 30, 2007* March 31,2007 January 19, 2007 January 21, 2002 March 31, 2002 March 30, 2007 September 18, 2006 a) December 24, 2006 b) March 30, 2007* c) March 30, 2007* d) September 18, 2006* a)january 19, 2007 b) a)january 19, 2007 b) b) b) a) December 25, 2007* b) March 05, 2008* January 21, 2007 January 21, 2007 * Extensions possible APPENDIX 1-7
Purpose of the Hatch-Waxman Act
Purpose of the Hatch-Waxman Act The purpose of the Act was to make available more low cost generic drugs by establishing a generic drug approval process for pioneer drugs first approved after 1962. H.R.
More informationCorrigendum. OECD Pensions Outlook 2012 DOI: ISBN (print) ISBN (PDF) OECD 2012
OECD Pensions Outlook 2012 DOI: http://dx.doi.org/9789264169401-en ISBN 978-92-64-16939-5 (print) ISBN 978-92-64-16940-1 (PDF) OECD 2012 Corrigendum Page 21: Figure 1.1. Average annual real net investment
More informationWhen Does A Little Equal Enough?
When Does A Little Equal Enough? Development and filing of an ANDA to market a generic drug requires many considerations. One important consideration concerns the evaluation of the patent landscape protecting
More informationInternational Statistical Release
International Statistical Release This release and additional tables of international statistics are available on efama s website (www.efama.org). Worldwide Investment Fund Assets and Flows Trends in the
More informationApproach to Employment Injury (EI) compensation benefits in the EU and OECD
Approach to (EI) compensation benefits in the EU and OECD The benefits of protection can be divided in three main groups. The cash benefits include disability pensions, survivor's pensions and other short-
More informationInternational Statistical Release
International Statistical Release This release and additional tables of international statistics are available on efama s website (www.efama.org) Worldwide Investment Fund Assets and Flows Trends in the
More informationInternational Statistical Release
International Statistical Release This release and additional tables of international statistics are available on efama s website (www.efama.org) Worldwide Investment Fund Assets and Flows Trends in the
More information8-Jun-06 Personal Income Top Marginal Tax Rate,
8-Jun-06 Personal Income Top Marginal Tax Rate, 1975-2005 2005 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 Australia 47% 47% 47% 47% 47% 47% 47% 47% 47% 47% 47% 48% 49% 49% Austria
More informationTAXATION OF TRUSTS IN ISRAEL. An Opportunity For Foreign Residents. Dr. Avi Nov
TAXATION OF TRUSTS IN ISRAEL An Opportunity For Foreign Residents Dr. Avi Nov Short Bio Dr. Avi Nov is an Israeli lawyer who represents taxpayers, individuals and entities. Areas of Practice: Tax Law,
More informationTable 1: Foreign exchange turnover: Summary of surveys Billions of U.S. dollars. Number of business days
Table 1: Foreign exchange turnover: Summary of surveys Billions of U.S. dollars Total turnover Number of business days Average daily turnover change 1983 103.2 20 5.2 1986 191.2 20 9.6 84.6 1989 299.9
More informationInternational Statistical Release
International Statistical Release This release and additional tables of international statistics are available on efama s website (www.efama.org) Worldwide Investment Fund Assets and Flows Trends in the
More informationGlossary of Defined Terms
Glossary of Defined Terms Glossary History Change Date April 2007 July 2007 Description of Changes Initial Launch Amendment of definition of administrator(s) Glossary History July 2007 Page 1 of 1 A Accredited
More informationImproving data on pharmaceuticals. Meeting of OECD Health Data National Correspondents 3-4 october 2011
Improving data on pharmaceuticals Meeting of OECD Health Data National Correspondents 3-4 october 2011 Purpose of this agenda item Present the current content of OECD health data on pharmaceuticals Propose
More informationRegistration of Foreign Limited Partnerships in the Cayman Islands
Registration of Foreign Limited Partnerships in the Cayman Islands Preface This publication has been prepared for the assistance of those who are considering registration of a foreign limited partnership
More informationAssessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing Exemption in the EU
White paper Assessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing Exemption in the EU Ramya Logendra, Engagement Manager, Supplier and Association Relations Per
More informationInternational Statistical Release
International Statistical Release This release and additional tables of international statistics are available on efama s website (www.efama.org). Worldwide Investment Fund Assets and Flows Trends in the
More informationFCCC/SBI/2010/10/Add.1
United Nations Framework Convention on Climate Change Distr.: General 25 August 2010 Original: English Subsidiary Body for Implementation Contents Report of the Subsidiary Body for Implementation on its
More informationTaiwan Generic Pharmaceutical Market Status & Issues
Taiwan Generic Pharmaceutical Market Status & Issues The 15th Annual IGPA Conference 2012 Kyoto, Japan Taiwan Generic Pharmaceutical Association Tiffany Chen OUTLINE Taiwan Pharmaceutical Market Overview
More informationOECD HEALTH SYSTEM CHARACTERISTICS SURVEY 2012
OECD HEALTH SYSTEM CHARACTERISTICS SURVEY 2012 Emily Hewlett OECD Health Data National Correspondents and Health Accounts Experts Meeting, 17 th October 2013 Health System Characteristics Survey 2012 HSC
More informationFEES SCHEDULE (COPPER / GOLD)
FEES SCHEDULE (COPPER / GOLD) Applicable from April 208 excluding discretionary management agreement and investment advisory agreement CBP Quilvest LU EN Fees Schedule Excluding Management April 208 /5
More informationSources of Government Revenue in the OECD, 2016
FISCAL FACT No. 517 July, 2016 Sources of Government Revenue in the OECD, 2016 By Kyle Pomerleau Director of Federal Projects Kevin Adams Research Assistant Key Findings OECD countries rely heavily on
More informationReporting practices for domestic and total debt securities
Last updated: 27 November 2017 Reporting practices for domestic and total debt securities While the BIS debt securities statistics are in principle harmonised with the recommendations in the Handbook on
More informationFEES SCHEDULE (SILVER/PLATINUM)
FEES SCHEDULE (SILVER/PLATINUM) Applicable from April 208 under an Investment Advisory Agreement CBP Quilvest LU EN Investment Advisory Fees Schedule April 208 /5 ADVISORY MANAGEMENT, CUSTODY FEES AND
More informationLow employment among the 50+ population in Hungary
Low employment among the + population in Hungary The role of incentives, health and cognitive capacities Janos Divenyi (Central European University) and Gabor Kezdi (Central European University and IE-CRSHAS)
More informationGrowth in OECD Unit Labour Costs slows to 0.4% in the third quarter of 2016
Growth in OECD Unit Labour Costs slows to.4% in the third quarter of 26 Growth in unit labour costs (ULCs) in the OECD area slowed to.4% in the third quarter of 26 (compared with.6% in the previous quarter)
More informationInternational Statistical Release
International Statistical Release This release and additional tables of international statistics are available on efama s website (www.efama.org). wide Regulated Open-ended Fund Assets and Flows Trends
More informationLONG-TERM PROJECTIONS OF PUBLIC PENSION EXPENDITURE
7. FINANCES OF RETIREMENT-INCOME SYSTEMS LONG-TERM PROJECTIONS OF PUBLIC PENSION EXPENDITURE Key results Public spending on pensions has been on the rise in most OECD countries for the past decades, as
More informationInternational Statistical Release
International Statistical Release This release and additional tables of international statistics are available on efama s website (www.efama.org). Worldwide Regulated Open-ended Fund Assets and Flows Trends
More information2018 INTERNATIONAL CONFERENCE ON MUNICIPAL FISCAL HEALTH U.S. Tax Reform and Its Impact on State and Local Government Finance Presented by Jane L.
2018 INTERNATIONAL CONFERENCE ON MUNICIPAL FISCAL HEALTH U.S. Tax Reform and Its Impact on State and Local Government Finance Presented by Jane L. Campbell ; Director NDC Washington Office National Development
More informationRecommendation of the Council on Tax Avoidance and Evasion
Recommendation of the Council on Tax Avoidance and Evasion OECD Legal Instruments This document is published under the responsibility of the Secretary-General of the OECD. It reproduces an OECD Legal Instrument
More informationCorporate taxes and intellectual property
Corporate taxes and intellectual property Rachel Griffith and Helen Miller Corporate tax reform Corporate Tax Reform: Delivering a More Competitive System HM Treasury (Nov 2010) competitive stable provide
More informationOutlook Overview: OECD Countries UN LINK Conference, Bangkok October, 2009
Outlook Overview: OECD Countries UN LINK Conference, Bangkok 26 28 October, 2009 Dave Turner OECD, Economics Department OECD Outlook: Outline 1. Recovery underway but will probably be slow 2. Risks and
More informationPension Fund Investment and Regulation - An International Perspective and Implications for China s Pension System
Pension Fund Investment and Regulation - An International Perspective and Implications for China s Pension System Yu-Wei Hu, Fiona Stewart and Juan Yermo Financial Affairs Division OECD, Paris OECD/IOPS
More informationStatistical annex. Sources and definitions
Statistical annex Sources and definitions Most of the statistics shown in these tables can be found as well in several other (paper or electronic) publications or references, as follows: the annual edition
More informationLearning Goal. To develop an understanding of the Millennium Development Goal targets
Learning Goal To develop an understanding of the Millennium Development Goal targets APK - Activity If you were to set up goals for the world to improve conditions for the world s people, what goals would
More informationTurkey s Saving Deficit Issue From an Institutional Perspective
Turkey s Saving Deficit Issue From an Institutional Perspective Engin KURUN, Ph.D CEO, Ziraat Asset Management Oct. 25th, 2011 - Istanbul 1 PRESENTATION Household and Institutional Savings Institutional
More informationFirst estimate for 2011 Euro area external trade deficit 7.7 bn euro bn euro deficit for EU27
27/2012-15 February 2012 First estimate for 2011 Euro area external trade deficit 7.7 152.8 deficit for EU27 The first estimate for the euro area 1 (EA17) trade in goods balance with the rest of the world
More informationMay 2012 Euro area international trade in goods surplus of 6.9 bn euro 3.8 bn euro deficit for EU27
108/2012-16 July 2012 May 2012 Euro area international trade in goods surplus of 6.9 3.8 deficit for EU27 The first estimate for the euro area 1 (EA17) trade in goods balance with the rest of the world
More informationIMPORTANT TAX INFORMATION
00126803 IMPORTANT TAX INFORMATION Dear Hartford Funds Shareholder: The following information about your enclosed 1099-DIV from Hartford Funds should be used when preparing your 2014 tax return. The information
More informationJune 2014 Euro area international trade in goods surplus 16.8 bn 2.9 bn surplus for EU28
127/2014-18 August 2014 June 2014 Euro area international trade in goods surplus 16.8 bn 2.9 bn surplus for EU28 The first estimate for the euro area 1 (EA18) trade in goods balance with the rest of the
More informationCollective Bargaining in OECD and accession countries
Collective Bargaining in OECD and accession countries www.oecd.org/employment/collective-bargaining.htm The, ultra-activity and retro-activity of collective agreements The detailed description of the building
More informationBank of Canada Triennial Central Bank Survey of Foreign Exchange and Over-the-Counter (OTC) Derivatives Markets
Bank of Canada Triennial Central Bank Survey of Foreign Exchange and Over-the-Counter (OTC) Derivatives Markets Turnover for, and Amounts Outstanding as at June 30, March, 2005 Turnover data for, Table
More informationThird Revised Decision of the Council concerning National Treatment
Third Revised Decision of the Council concerning National Treatment OECD Legal Instruments This document is published under the responsibility of the Secretary-General of the OECD. It reproduces an OECD
More informationJune 2012 Euro area international trade in goods surplus of 14.9 bn euro 0.4 bn euro surplus for EU27
121/2012-17 August 2012 June 2012 Euro area international trade in goods surplus of 14.9 0.4 surplus for EU27 The first estimate for the euro area 1 (EA17) trade in goods balance with the rest of the world
More informationSources of Government Revenue in the OECD, 2017
FISCAL FACT No. 558 Aug. 2017 Sources of Government Revenue in the OECD, 2017 Amir El-Sibaie Analyst Key Findings: OECD countries rely heavily on consumption taxes, such as the value-added tax, and social
More informationSources of Government Revenue in the OECD, 2018
FISCAL FACT No. 581 Mar. 2018 Sources of Government Revenue in the OECD, 2018 Amir El-Sibaie Analyst Key Findings In 2015, OECD countries relied heavily on consumption taxes, such as the value-added tax,
More informationStatistical Annex ANNEX
ISBN 92-64-02384-4 OECD Employment Outlook Boosting Jobs and Incomes OECD 2006 ANNEX Statistical Annex Sources and definitions Most of the statistics shown in these tables can be found as well in three
More informationEFFECTIVE DATE August 17, ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors
Valeant Pharmaceuticals International, Inc. POLICY NO. H.R. Sec. 9 914 EFFECTIVE DATE August 17, 2016 PAGE NO. 1 of 9 SUBJECT: ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors
More informationAgeing and employment policies: Ireland
Ageing and employment policies: Ireland John Martin 1 Director for Employment, Labour and Social Affairs, OECD FÁS Annual Labour Market Conference, Dublin, 5 December 2005 OECD has carried out a major
More informationPaying providers to increase Value for Money: Is Pay for Performance the Answer? Review of OECD experience
Paying providers to increase Value for Money: Is Pay for Performance the Answer? Review of OECD experience Michael Borowitz OECD Health Division SBO Network on Health Expenditures 1 Productivity Challenge:
More informationDouble Tax Treaties. Necessity of Declaration on Tax Beneficial Ownership In case of capital gains tax. DTA Country Withholding Tax Rates (%)
Double Tax Treaties DTA Country Withholding Tax Rates (%) Albania 0 0 5/10 1 No No No Armenia 5/10 9 0 5/10 1 Yes 2 No Yes Australia 10 0 15 No No No Austria 0 0 10 No No No Azerbaijan 8 0 8 Yes No Yes
More informationOECD Health Policy Unit. 10 June, 2001
The State of Implementation of the OECD Manual: A System of Health Accounts (SHA) in OECD Member Countries, 2001 OECD Health Policy Unit 10 June, 2001 TABLE OF CONTENTS Summary...3 Introduction...4 Background
More informationForeign Account Tax Compliance Act (FATCA)
Foreign Account Tax Compliance Act (FATCA) Impact Assessment on the Financial Services (Banking and Insurance) sectors and businesses in Trinidad and Tobago Presentation by the Bankers Association of Trinidad
More informationOECD Report Shows Tax Burdens Falling in Many OECD Countries
OECD Centres Germany Berlin (49-30) 288 8353 Japan Tokyo (81-3) 5532-0021 Mexico Mexico (52-55) 5281 3810 United States Washington (1-202) 785 6323 AUSTRALIA AUSTRIA BELGIUM CANADA CZECH REPUBLIC DENMARK
More informationMarch 2005 Euro-zone external trade surplus 4.2 bn euro 6.5 bn euro deficit for EU25
STAT/05/67 24 May 2005 March 2005 Euro-zone external trade surplus 4.2 6.5 deficit for EU25 The first estimate for euro-zone 1 trade with the rest of the world in March 2005 was a 4.2 billion euro surplus,
More informationTrends in the European Investment Fund Industry. in the First Quarter of 2013
Quarterly Statistical Release May 2013, N 53 This release and other statistical releases are available on efama s website (www.efama.org) Trends in the European Investment Fund Industry in the First Quarter
More informationEligibility? Activities covered? Clients covered? Application or notification required? N/A N/A N/A N/A N/A N/A N/A
NO DEAL BREXIT TRACKER Governments in European Economic Area (EEA) member states are announcing domestic measures in order to prepare for the UK's withdrawal from the EEA. The table below monitors these
More informationDG TAXUD. STAT/11/100 1 July 2011
DG TAXUD STAT/11/100 1 July 2011 Taxation trends in the European Union Recession drove EU27 overall tax revenue down to 38.4% of GDP in 2009 Half of the Member States hiked the standard rate of VAT since
More informationEFFECTIVE DATE November 1, ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors
Valeant Pharmaceuticals International, Inc. POLICY NO. H.R. Sec. 9 914 EFFECTIVE DATE November 1, 2013 PAGE NO. 1 of 9 SUBJECT: ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors
More information10% 10% 15% 15% Caseload: WE. 15% Caseload: SS 10% 10% 15%
Percentchangeincaseload 15% 10% 5% 0% 5% 10% 15% Caseload: AO 0 1 2 3 4 5 Percentchangein caseload 15% 10% 5% 0% 5% 10% 15% Caseload: NC 0 1 2 3 4 5 Years Years Percentchangein caseload 15% 10% 5% 0% 5%
More informationSTATISTICS. Taxing Wages DIS P O NIB LE E N SPECIAL FEATURE: PART-TIME WORK AND TAXING WAGES
AVAILABLE ON LINE DIS P O NIB LE LIG NE www.sourceoecd.org E N STATISTICS Taxing Wages «SPECIAL FEATURE: PART-TIME WORK AND TAXING WAGES 2004-2005 2005 Taxing Wages SPECIAL FEATURE: PART-TIME WORK AND
More informationThe Case for Fundamental Tax Reform: Overview of the Current Tax System
The Case for Fundamental Tax Reform: Overview of the Current Tax System Sources of Federal Receipts Projected for 2016 Excise Taxes 2.9% Estate & Gift Taxes 0.6% Corporate Income Taxes 9.8% Other Taxes
More informationPENSIONS IN OECD COUNTRIES: INDICATORS AND DEVELOPMENTS
PENSIONS IN OECD COUNTRIES: INDICATORS AND DEVELOPMENTS Marius Lüske Directorate for Employment, Labour and Social Affairs, OECD Lisbon, 28.09.2018 Marius.LUSKE@oecd.org www.oecd.org/els OUTLINE Talk based
More informationJanuary 2014 Euro area international trade in goods surplus 0.9 bn euro 13.0 bn euro deficit for EU28
STAT/14/41 18 March 2014 January 2014 Euro area international trade in goods surplus 0.9 13.0 deficit for EU28 The first estimate for the euro area 1 (EA18) trade in goods balance with the rest of the
More informationFUTURE TAXATION OF COMPANY PROFITS
FUTURE TAXATION OF COMPANY PROFITS What to do with intangibles? Presentation at Taxation of the digitalised economy: analysing the OECD approach event 19-02-2019 WHAT IS BEING PROPOSED? SMALL INNOVATIVE
More informationAnnex 4: Summary of R&D tax incentives,
Annex 4: Summary of R&D tax incentives, 2008-2009 Country Corporate income tax rate large/small firm Rate on level Rate on Base for 1 Expense base Deducted from European Union and EEC Countries Austria
More informationFSMA_2017_05-01 of 24/02/2017
FSMA_2017_05-01 of 24/02/2017 This Communication is addressed to Belgian alternative investment fund managers who intend to market, to professional investors, units or shares of European Economic Area
More informationWerte schaffen durch Innovation: Pharma Prof. Dr. Wolfram Carius LMU München,
Werte schaffen durch Innovation: Pharma 2020 Prof. Dr. Wolfram Carius LMU München, 26.11.2010 External Situation: Market environment and Competition General Economy Political Environment 1) Market environment
More informationVinodh & Muthu. Tax Alert. Insight. Chartered Accountants. Country by Country Reporting & Master File
Vinodh & Muthu Chartered Accountants Tax Alert Country by Country Reporting & Master File Insight The Organisation for Economic Cooperation and Development ( OECD ) report on Action 13 of Base Erosion
More informationBalanced Plus Select Portfolio Pn
Factsheet as at : August 25, 2018 Balanced Plus Select Portfolio Pn Fund objective This portfolio aims to provide long-term capital growth while keeping risk in a target volatility range of 10-12% over
More informationRecommendation of the Council on the Implementation of the Polluter-Pays Principle
Recommendation of the Council on the Implementation of the Polluter-Pays Principle OECD Legal Instruments This document is published under the responsibility of the Secretary-General of the OECD. It reproduces
More informationHousehold Financial Wealth By Selected Country
Household Financial Wealth By Selected Country US$ Trillions 60 50-37% Indicates Projected Shortfall 40 30 20 Extrapolation of Historical Growth 2003-24 Projection (Based on Demographic Trends) -47% -34%
More informationRev. Proc Implementation of Nonresident Alien Deposit Interest Regulations
Rev. Proc. 2012-24 Implementation of Nonresident Alien Deposit Interest Regulations SECTION 1. PURPOSE Sections 1.6049-4(b)(5) and 1.6049-8 of the Income Tax Regulations, as revised by TD 9584, require
More informationNasdaq Global ex-australia Sector Indexes Methodology
Nasdaq Global ex-australia Sector Indexes Methodology Index Description Australia Sector Indexes are designed to track the performance of global ex-australian companies that are in the Bank, Healthcare
More informationHEALTH: FOCUS ON TOMORROW S NEEDS. Date:7 th December Overview of the Irish Healthcare System John O Dwyer CEO, Vhi Group DAC.
HEALTH: FOCUS ON TOMORROW S NEEDS Overview of the Irish Healthcare System John O Dwyer CEO, Vhi Group DAC Date:7 th December 2018 Agenda Agenda Irish Economic Landscape Overview of the Irish Healthcare
More informationGlobal Economic Briefing: Global Inflation
Global Economic Briefing: Global Inflation November, 7 Dr. Edward Yardeni -97-7 eyardeni@ Debbie Johnson -- djohnson@ Mali Quintana -- aquintana@ Please visit our sites at www. blog. thinking outside the
More informationEVCA Private Equity Activity Survey 2007 Europe
EVCA Private Equity Activity Survey 2007 Europe 31 Europe 2006 Highlights: Demonstrating confidence in the European private equity sector with a record fundraising level of 112.3 billion in 2006, a significant
More informationFinancial Globalization, governance, and the home bias. Bong-Chan Kho, René M. Stulz and Frank Warnock
Financial Globalization, governance, and the home bias Bong-Chan Kho, René M. Stulz and Frank Warnock Financial globalization Since end of World War II, dramatic reduction in barriers to international
More informationSummary of key findings
1 VAT/GST treatment of cross-border services: 2017 survey Supplies of e-services to consumers (B2C) (see footnote 1) Supplies of e-services to businesses (B2B) 1(a). Is a non-resident 1(b). If there is
More informationBank of Canada Triennial Central Bank Surveys of Foreign Exchange and Over-the-Counter (OTC) Derivatives Markets Turnover for April, 2007 and Amounts
Bank of Canada Triennial Central Bank Surveys of Foreign Exchange and Over-the-Counter (OTC) Derivatives Markets Turnover for April, 2007 and Amounts Outstanding as at June 30, 2007 January 4, 2008 Table
More informationAugust 2012 Euro area international trade in goods surplus of 6.6 bn euro 12.6 bn euro deficit for EU27
146/2012-16 October 2012 August 2012 Euro area international trade in goods surplus of 6.6 12.6 deficit for EU27 The first estimate for the euro area 1 (EA17) trade in goods balance with the rest of the
More informationTHE ADVISOR March 18, 2008
Withholding Taxes Part 2 THE ADVISOR March 18, 2008 The Impact on Non-Residents Investing through an Account in Canada Prashant Patel, ASA, CFP, TEP, Wealth Management Services Michelle Munro, CA, Wealth
More informationFinancial wealth of private households worldwide
Economic Research Financial wealth of private households worldwide Munich, October 217 Recovery in turbulent times Assets and liabilities of private households worldwide in EUR trillion and annualrate
More informationUS Reimbursement Systems: Effects on R&D
US Reimbursement Systems: Effects on R&D Patricia M. Danzon, PhD Professor Emeritus The Wharton School University of Pennsylvania Theory: Optimal Reimbursement Rules to Create Efficient R&D Incentives
More informationInternational Services tariff
International Services tariff Contents International Services Sending money abroad 1 International payments 1 Receiving money from abroad 1 Cut-off times and exchange rates 2 BIC and IBAN two numbers you
More informationBRITISH EXPORTERS ASSOCIATION
BRITISH EXPORTERS ASSOCIATION Broadway House, Tothill Street, London SW1H 9NQ Tel.: 020 7222 5419 FAX: 020 7799 2468 email: hughbailey@bexa.co.uk www.bexa.co.uk 9 th October 2015 Overview of BExA Concessional
More informationUpdates and revisions of national SUTs for the November 2013 release of the WIOD
Updates and revisions of national SUTs for the November 2013 release of the WIOD Edited by Marcel Timmer (University of Groningen) With contributions from: Abdul A. Erumban, Reitze Gouma and Gaaitzen J.
More informationJanuary 2005 Euro-zone external trade deficit 2.2 bn euro 14.0 bn euro deficit for EU25
42/2005-23 March 2005 January 2005 Euro-zone external trade deficit 2.2 14.0 deficit for EU25 The first estimate for euro-zone 1 trade with the rest of the world in January 2005 was a 2.2 billion euro
More informationIntroduction 283,602,000,000 ( 284 billion ) 71 billion 10.71%
Introduction Over the last 4 years (between 2012 to 2015 inclusive) the UK has imported 283,602,000,000 ( 284 billion ) more from the rest of the EU than the UK and NI have exported to the EU resulting
More informationLatest regulatory update in the insurance industry Actuarial & Insurance Solutions
Latest regulatory update in the insurance industry Actuarial & Insurance Solutions July 2018 Latest regulatory update in the insurance industry Actuarial & Insurance Solutions July 2018 2 Twin Peaks is
More informationSwitzerland and Germany top the PwC Young Workers Index in developing younger people
Press release Date 9 November 2015 Contact Mihnea Anastasiu Pages 5 Media Relations Manager Tel: +40 21 225 3546 Email: mihnea.anastasiu@ro.pwc.com Switzerland and Germany top the PwC Young Workers Index
More informationMay 2009 Euro area external trade surplus 1.9 bn euro 6.8 bn euro deficit for EU27
STAT/09/106 17 July 2009 May 2009 Euro area external trade surplus 1.9 6.8 deficit for EU27 The first estimate for the euro area 1 (EA16) trade balance with the rest of the world in May 2009 gave a 1.9
More informationTerms and Conditions for Payments by Direct Debit under the SEPA Core Direct Debit Scheme
Terms and Conditions for Payments by Direct Debit under the SEPA Core Direct Debit Scheme Payments which the customer makes to payees (creditors) by SEPA core direct debit through his/her account with
More informationBurden of Taxation: International Comparisons
Burden of Taxation: International Comparisons Standard Note: SN/EP/3235 Last updated: 15 October 2008 Author: Bryn Morgan Economic Policy & Statistics Section This note presents data comparing the national
More informationDANMARKS NATIONALBANK
DANMARKS NATIONALBANK WEALTH, DEBT AND MACROECONOMIC STABILITY Niels Lynggård Hansen, Head of Economics and Monetary Policy. IARIW, Copenhagen, 21 August 2018 Agenda Descriptive evidence on household debt
More informationAugust 2005 Euro-zone external trade deficit 2.6 bn euro 14.2 bn euro deficit for EU25
STAT/05/132 20 October 2005 August 2005 Euro-zone external trade deficit 2.6 14.2 deficit for EU25 The first estimate for euro-zone 1 trade with the rest of the world in August 2005 was a 2.6 billion euro
More informationBEPS Actions implementation by country Actions 8-10 Transfer pricing
BEPS Actions implementation by country Actions 8-10 Transfer pricing On 5 October 2015, the G20/OECD published 13 final reports and an explanatory statement outlining consensus actions under the base erosion
More informationHealth Care in Crisis
Health Care in Crisis The Economic Imperative for Health Care Reform James Kvaal and Ben Furnas February 19, 2009 1 Center for American Progress Health Care in Crisis U.S. spends twice as much per capita
More information2.2. The client understands and agrees that in order to execute payments by SEPA direct debit:
SATABANK SEPA DIRECT DEBIT DEBTOR SERVICE Approved by BoD of Satabank: 9 th of August, 2016 This Schedule applies to SEPA Direct debit payments, which the Client of Satabank makes as a Debtor (payer) to
More informationOpen Day 2017 Clearstream execution-to-custody integration Valentin Nehls / Jan Willems. 5 October 2017
Open Day 2017 Clearstream execution-to-custody integration Valentin Nehls / Jan Willems 5 October 2017 Deutsche Börse Group 1 Settlement services: single point of access to cost-effective, low risk and
More information